CYDY AMAZING PROGRESS: - Clear path to completin
Post# of 148190
(Total Views: 1389)
Posted On: 10/21/2020 9:13:38 PM
CYDY AMAZING PROGRESS:
- Clear path to completing CD12 trial successfully has been provided. DMSC has made some clever recommendations. Love their confidence shown by adding another interim milestone at 75% enrollment with 48 days extended measuring window.
- Extra emphasis with dedicated CYDY resources to communicate and help testing sites to help accelerate. New testing sites being added. Will get to target in 6 weeks or less with this driven focus by NP!
- New CSO very experienced, will get BLA and supporting activities done and subsequent operational issues as we start revenue generating operations. HIV treatment revolution next year including prevention usage!
- Oncology programs gets a NEW full time experienced add. Emphasis on mTNBC and basket trials. This will accelerate the effort to get to the Break Through Designation. Huge milestone and SP increase!
- Philippines and U.K. getting hot! Building momentum to move product as soon as we get to the next interim milestone independent of the FDA.
- First of several peer reviewed papers (Dr. Otto Yang, et al..) hit the press for the medical community to digest the MOA of our monoclonal antibody LL. More papers to come. This is just the start of the revolution, the ball is rolling down the hill.
- Read the confirmation of Ohm’s explanation of LL impacting the virus directly by recent, third party, research publications. This is in addition to Dr. Patterson hypothesis of a rebalanced immune system clearing out the invading viruses. Lots more learning to come but we know the final effects in just a few days. Hope Dr. P’s paper sees the light of day soon.
- Long haulers, hang in there LL is coming to your rescue. Trials started by year end. Crossing the blood brain barrier is an amazing find! Consequences are astronomical. More science but therapeutic consequences are monumental, don’t you think?
FORECAST: Stock price will hit $8-10 by year end!
- Clear path to completing CD12 trial successfully has been provided. DMSC has made some clever recommendations. Love their confidence shown by adding another interim milestone at 75% enrollment with 48 days extended measuring window.
- Extra emphasis with dedicated CYDY resources to communicate and help testing sites to help accelerate. New testing sites being added. Will get to target in 6 weeks or less with this driven focus by NP!
- New CSO very experienced, will get BLA and supporting activities done and subsequent operational issues as we start revenue generating operations. HIV treatment revolution next year including prevention usage!
- Oncology programs gets a NEW full time experienced add. Emphasis on mTNBC and basket trials. This will accelerate the effort to get to the Break Through Designation. Huge milestone and SP increase!
- Philippines and U.K. getting hot! Building momentum to move product as soon as we get to the next interim milestone independent of the FDA.
- First of several peer reviewed papers (Dr. Otto Yang, et al..) hit the press for the medical community to digest the MOA of our monoclonal antibody LL. More papers to come. This is just the start of the revolution, the ball is rolling down the hill.
- Read the confirmation of Ohm’s explanation of LL impacting the virus directly by recent, third party, research publications. This is in addition to Dr. Patterson hypothesis of a rebalanced immune system clearing out the invading viruses. Lots more learning to come but we know the final effects in just a few days. Hope Dr. P’s paper sees the light of day soon.
- Long haulers, hang in there LL is coming to your rescue. Trials started by year end. Crossing the blood brain barrier is an amazing find! Consequences are astronomical. More science but therapeutic consequences are monumental, don’t you think?
FORECAST: Stock price will hit $8-10 by year end!
(16)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼